Cargando…

Development of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye disease

Dry eye disease (DED) is a multifactorial disorder of the ocular surface characterized by symptoms of discomfort, decreased tear quality, and chronic inflammation that affects an estimated 20 million patients in the US alone. DED is associated with localized inflammation of the ocular surface and pe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Semba, Charles P, Gadek, Thomas R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4910612/ https://www.ncbi.nlm.nih.gov/pubmed/27354762 http://dx.doi.org/10.2147/OPTH.S110557

Ejemplares similares

Dry eye syndrome: developments and lifitegrast in perspective
por: Lollett, Ivonne V, et al.
Publicado: (2018)

Lifitegrast: a novel drug for patients with dry eye disease
por: Haber, Stacy L., et al.
Publicado: (2019)

Lifitegrast: A novel drug for treatment of dry eye disease
por: Abidi, Afroz, et al.
Publicado: (2016)

Lifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapy
por: Godin, Morgan R, et al.
Publicado: (2017)

Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study
por: Donnenfeld, Eric D., et al.
Publicado: (2016)

The Effect of Lifitegrast on Refractive Accuracy and Symptoms in Dry Eye Patients Undergoing Cataract Surgery
por: Hovanesian, John, et al.
Publicado: (2020)

LIFITEGRAST 5% FOR DRY EYE DISEASE: COMBINED EFFICACY AND SAFETY FROM FIVE RANDOMIZED CONTROLLED TRIALS
por: Gonzalez, Agustin L, et al.
Publicado: (2019)

Lifitegrast Ophthalmic Solution 5% Is a Safe and Efficient Eyedrop for Dry Eye Disease: A Systematic Review and Meta-Analysis
por: Li, Jing-Xing, et al.
Publicado: (2022)

Longitudinal changes in dry eye symptoms and signs following lifitegrast therapy and relationship to tear osmolarity
por: Pepose, Jay S, et al.
Publicado: (2019)

Six months' treatment with lifitegrast in patients with moderate-to-severe symptomatic dry eye: a retrospective chart review
por: Atallah, Richard Teofilo, et al.
Publicado: (2019)

Real-World Treatment Patterns Of Cyclosporine Ophthalmic Emulsion And Lifitegrast Ophthalmic Solution Among Patients With Dry Eye
por: White, Darrell E, et al.
Publicado: (2019)

Safety and tolerability of lifitegrast ophthalmic solution 5.0%: Pooled analysis of five randomized controlled trials in dry eye disease
por: Nichols, Kelly K, et al.
Publicado: (2018)

A Post-Acute Ocular Tolerability Comparison of Topical Reproxalap 0.25% and Lifitegrast 5% in Patients with Dry Eye Disease
por: McMullin, David, et al.
Publicado: (2021)

Reduction of Artificial Tears and Use of Adjunctive Dry Eye Therapies After Lifitegrast Treatment: Evidence from Clinical and Real-World Studies
por: Nichols, Kelly K, et al.
Publicado: (2022)

Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysis
por: Karpecki, Paul, et al.
Publicado: (2023)

Real-World Experience with Lifitegrast Ophthalmic Solution (Xiidra(®)) in the US and Canada: Retrospective Study of Patient Characteristics, Treatment Patterns, and Clinical Effectiveness in 600 Patients with Dry Eye Disease
por: Hovanesian, John A, et al.
Publicado: (2021)

Efficacy of Lifitegrast Ophthalmic Solution, 5.0%, in Patients With Moderate to Severe Dry Eye Disease: A Post Hoc Analysis of 2 Randomized Clinical Trials
por: Holland, Edward J., et al.
Publicado: (2021)

Lifitegrast add-on treatment for dupilumab-induced ocular surface disease (DIOSD): A novel case report
por: Zirwas, Matthew J., et al.
Publicado: (2018)

Matching-adjusted indirect comparison of phase 3 clinical trial outcomes of OC-01 (varenicline solution) nasal spray and lifitegrast 5% ophthalmic solution for the treatment of dry eye disease
por: White, Darrell E, et al.
Publicado: (2023)

Ocular Distribution and Pharmacokinetics of Lifitegrast in Pigmented Rabbits and Mass Balance in Beagle Dogs
por: Chung, Jou-Ku, et al.
Publicado: (2018)

Safety and efficacy of lifitegrast 5% ophthalmic solution in contact lens discomfort
por: Gonzalez, Agustin L
Publicado: (2018)

Hyaluronic acid in the treatment of dry eye disease
por: Hynnekleiv, Leif, et al.
Publicado: (2022)

Current Management and Treatment of Dry Eye Disease
por: Şimşek, Cem, et al.
Publicado: (2018)

Design, synthesis, and LFA-1/ICAM-1 antagonist activity evaluation of Lifitegrast analogues
por: Du, Guoxin, et al.
Publicado: (2022)

Loteprednol Etabonate for the Treatment of Dry Eye Disease
por: Beckman, Kenneth, et al.
Publicado: (2020)

Chloroquine and Hydroxychloroquine in the Treatment of Dry Eye Disease
por: Prinz, Julia, et al.
Publicado: (2023)

Recent developments on dry eye disease treatment compounds
por: Colligris, Basilio, et al.
Publicado: (2014)

Honey-Related Treatment Strategies in Dry Eye Disease
por: Prinz, Julia, et al.
Publicado: (2023)

Novel therapeutics for dry eye disease
por: Wu, Duoduo, et al.
Publicado: (2023)

Practical Synthesis of 5,7-Dichlorotetrahydroisoquinoline-6-carboxylic Acid—Key Intermediate of Lifitegrast (Xiidra)
por: Liu, Xu, et al.
Publicado: (2023)

Recent Advances in Hydrogels for the Diagnosis and Treatment of Dry Eye Disease
por: Li, Qiaoqiao, et al.
Publicado: (2022)

Formulation Considerations for the Management of Dry Eye Disease
por: Agarwal, Priyanka, et al.
Publicado: (2021)

Keratoprosthesis in dry eye disease
por: Sharma, Supriya, et al.
Publicado: (2023)

Development and content validity assessment of the Dry Eye Disease Questionnaire in patients with dry eye disease, meibomian gland dysfunction, and Sjögren’s syndrome dry eye disease
por: Sloesen, Brigitte, et al.
Publicado: (2023)

Treatment of chronic dry eye: focus on cyclosporine
por: Kymionis, George D, et al.
Publicado: (2008)

Why the symptoms and objective signs of dry eye disease may not correlate
por: McMonnies, Charles W.
Publicado: (2021)

Combination of hyaluronic acid, carmellose, and osmoprotectants for the treatment of dry eye disease
por: Mateo Orobia, Antonio José, et al.
Publicado: (2018)

New Perspectives in the Pathophysiology and Treatment of Pain in Patients with Dry Eye Disease
por: Giannaccare, Giuseppe, et al.
Publicado: (2021)

Dry Eye: an Inflammatory Ocular Disease
por: Hessen, Michelle, et al.
Publicado: (2014)

Development of Lutein-Containing Eye Drops for the Treatment of Dry Eye Syndrome
por: Chen, Yi-Zhou, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_oogcdq47sd4q4g4ri427o1flgo